tiprankstipranks
Xenon Pharmaceuticals initiated with a Buy at Goldman Sachs
The Fly

Xenon Pharmaceuticals initiated with a Buy at Goldman Sachs

Goldman Sachs analyst Paul Choi initiated coverage of Xenon Pharmaceuticals with a Buy rating and $60 price target. The company offers "innovation and blockbuster potential in an overlooked neuro category," Choi tells investors in a research note. The analyst sees near-to-medium term stock performance driven primarily by updates on XEN1101 in focal onset seizure, which he views as a "largely de-risked" lead indication.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on XENE:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles